Altimmune, Inc., a pioneering clinical-stage biopharmaceutical company specializing in the development of innovative peptide-based therapeutics, has successfully raised $200 million in its latest funding round. This significant financial boost will propel the company’s critical research and development efforts, particularly focusing on its lead product candidate, pemvidutide. Pemvidutide is a GLP-1/glucagon dual receptor agonist designed to combat obesity and nonalcoholic steatohepatitis (NASH), two pressing health concerns that affect millions globally. With obesity rates climbing and liver diseases on the rise, Altimmune’s work sits at the intersection of urgent public health needs and cutting-edge therapeutic innovation.
In addition to pemvidutide, the funding will also support the advancement of HepTcell™, an immunotherapeutic agent cultivated to achieve a functional cure for chronic hepatitis B—an infection that poses significant long-term health risks, including liver cancer. The newly secured capital not only underscores investor confidence in Altimmune's promising pipeline but also empowers the company to expedite its clinical trials and bring these groundbreaking treatments to market. As Altimmune continues to make strides in the biopharmaceutical landscape, the commitment to addressing obesity and liver diseases is paving the way for transformative healthcare solutions that could improve the lives of countless individuals battling these persistent and often debilitating conditions. The company is enthusiastic about leveraging this funding to advance its mission and tackle some of the most significant health challenges of our time.
